Biotech Intuition

Daily - Oct 22, 2026 - Show Notes

Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com

SUMMARY
Welcome to the SOZO biotech daily brief. Today, our lead stories cover an FDA accelerated approval for AstraZeneca in primary immunoglobulin A nephropathy, mid-stage clinical trial results from Lumen Bioscience in Clostridioides difficile, and a multi-target miniprotein discovery alliance between Astellas Pharma and AI Proteins. We also follow pipeline progress from Newron Pharmaceuticals and Thiogenesis Therapeutics, alongside new venture backing for Reju Therapeutics. Sources are in the show notes.

CHAPTERS AND SOURCES

00:00 - SOZO Biotech Daily Brief

00:34 - AstraZeneca's Ultomiris Wins FDA Accelerated Approval
Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A…:
https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html

01:38 - Lumen Reports Phase 2 RePreve Results for LMN-201
Lumen's LMN-201 shows positive RePreve Phase 2 results in C. difficile 2026-10-22:
https://www.lumen.bio/2026/10/22/lumen-s-lmn-201-shows-positive-re-preve-results-in-c-difficile

02:32 - Astellas and AI Proteins Form Miniprotein Discovery Pact
Astellas Pharma and AI Proteins enter miniprotein discovery collaboration valued at over $400 million 2026-10-21:
https://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million

03:18 - Newron Completes Phase 3 ENIGMA-TRS 1 Enrollment
Newron completes enrollment of pivotal Phase 3 ENIGMA-TRS 1 study of evenamide 2026-10-22:
https://www.newron.com/news-and-media/regulatory-news/newron-completes-enrollment-pivotal-phase-3-enigma-trs-1-study

03:54 - FDA Clears TTI-0102 IND in Nephropathic Cystinosis
Thiogenesis announces FDA clearance of IND for TTI-0102 in nephropathic cystinosis 2026-10-22:
https://finance.yahoo.com/healthcare/articles/thiogenesis-announces-fda-clearance-ind-090000510.html

04:29 - Nanjing Reju Therapeutics Closes Oversubscribed Series A
Reju Therapeutics completes oversubscribed Series A financing 2026-10-21:
https://www.vcbeathealth.com/article/63807

04:57 - Looking ahead

05:32 - SOZO Intuition

Daily - Oct 21, 2026 - Show Notes

Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com

CHAPTERS
00:00 SOZO Biotech Daily Brief
00:35 Fenebrutinib Cuts Relapse Rate in Multiple Sclerosis
01:11 Fenebrutinib Slows Chronic Brain Lesion Progression
01:46 Genentech Highlights Pediatric Ocrevus and Enspryng
02:23 Miv-cel Shows 1-Year Mobility Gains in Stiff Person
03:00 Miv-cel Enables Immunotherapy Freedom at One Year
03:38 Oral Olorofim Meets Non-Inferiority in Aspergillosis
04:12 Olorofim Reduces Renal Injury; Resubmission Planned
04:48 FDA Approves ORLADEYO Oral Pellets for HAE
05:30 LMN-201 Biologic Cocktail Succeeds in Phase 2 C. diff
06:13 BIOX-101 Reduces Edema Growth in Brain Hemorrhage
06:56 Servier Partners with Okomera on Tumor Miniaturization
07:37 Looking ahead
08:24 SOZO Intuition

SUMMARY

SOURCES BY CHAPTER

SOZO BIOTECH DAILY BRIEF

FENEBRUTINIB CUTS RELAPSE RATE IN MULTIPLE SCLEROSIS
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21:
https://www.gene.com/media/press-releases/15139/2026-10-21/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026

FENEBRUTINIB SLOWS CHRONIC BRAIN LESION PROGRESSION

GENENTECH HIGHLIGHTS PEDIATRIC OCREVUS AND ENSPRYNG

MIV-CEL SHOWS 1-YEAR MOBILITY GAINS IN STIFF PERSON
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto…:
https://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.html
Quell Therapeutics Advances QEL-005 to Second Dose Cohort in CHILL Phase 1/2 Trial in Rheumatoid Arthritis and Systemic Sclerosis 2026-10-21:
https://www.biospace.com/press-releases/promising-early-safety-data-as-quell-therapeutics-advances-qel-005-a-novel-engineered-ntreg-therapy-to-second-dose-cohort-in-chill-phase-1-2-trial-in-difficult-to-treat-rheumatoid-arthritis-and-systemic-sclerosis
Arctic Therapeutics Closes Oversubscribed US$21.5 Million Financing 2026-10-21:
https://www.prnewswire.com/news-releases/arctic-therapeutics-closes-oversubscribed-us21-5-million-financing-302915211.html

MIV-CEL ENABLES IMMUNOTHERAPY FREEDOM AT ONE YEAR

ORAL OLOROFIM MEETS NON-INFERIORITY IN ASPERGILLOSIS
Shionogi and F2G Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome Followed by Standard of Care in Invasive…:
https://www.shionogi.com/global/en/news/2026/10/e20261021_3.html

OLOROFIM REDUCES RENAL INJURY; RESUBMISSION PLANNED

FDA APPROVES ORLADEYO ORAL PELLETS FOR HAE
BioCryst Announces U.S. FDA Approval of ORLADEYO 150 mg Oral Pellets for Adults and Adolescents with Hereditary Angioedema 2026-10-21:
https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html

LMN-201 BIOLOGIC COCKTAIL SUCCEEDS IN PHASE 2 C. DIFF
Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial of LMN-201 for C. difficile Infection 2026-10-21:
https://www.prnewswire.com/news-releases/lumen-bio-reports-positive-phase-2-results-from-the-repreve-clinical-trial-lmn-201-for-c-difficile-infection-302915046.html

BIOX-101 REDUCES EDEMA GROWTH IN BRAIN HEMORRHAGE
Bioxodes BIOX-101 Phase 2a Data Show Statistically Significant Reduction in Perihematomal Edema Growth in Intracerebral Hemorrhage 2026-10-21:
https://www.bioxodes.com/newsroom/press-releases/bioxodes-biox-101-phase-2a-data-show-statistically-significant-reduction-in-perihematomal-edema-growth-in-intracerebral-hemorrhage

SERVIER PARTNERS WITH OKOMERA ON TUMOR MINIATURIZATION
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research 2026-10-21:
https://www.okomera.com/_files/ugd/631ec0_f041bdf1df614649962c581bf1a5e735.pdf

LOOKING AHEAD
Akeso Announces Summit Therapeutics and ECOG-ACRIN Enter a Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer…:
https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.html
Muna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator MNA-001 in Alzheimer Disease 2026-10-21:
https://www.prnewswire.com/news-releases/muna-therapeutics-announces-positive-phase-1-results-supporting-potential-of-oral-small-molecule-trem2-modulator-mna-001-in-alzheimers-disease-302914619.html
Additional references omitted to fit YouTube's 5,000-character limit.

Daily - Oct 20, 2026 v2 - Show Notes

Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com

CHAPTERS
00:00 Biotech Daily Briefing
00:43 RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
01:32 RAP-219 Validates Selective Mechanism in Acute Mania
02:12 Casdatifan Shows Efficacy in Renal Cell Carcinoma
03:02 Casdatifan Delivers 35-Month Median Overall Survival
03:46 Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
04:43 FDA Approves Process 2.0 for Alvotech's SIMLANDI
05:27 Ambrose Acquires AM-Pharma for up to 161 Million Euros
06:16 Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
07:06 Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
07:50 Looking ahead
08:31 SOZO Intuition

SUMMARY
Welcome to today's biotech daily briefing. Today, we lead with positive mid-stage clinical proof-of-concept data from Rapport Therapeutics in acute bipolar mania, expansive platform trial results from Arcus Biosciences evaluating casdatifan across multiple lines of clear cell renal cell carcinoma, and long-term extension data from Teva and Sanofi demonstrating sustained efficacy for duvakitug in inflammatory bowel disease. We also follow regulatory and clinical advancements spanning biomanufacturing, rare disease acquisitions, critical care respiratory medicine, and gastrointestinal oncology. Sources are in the show notes.

CHAPTERS AND SOURCES

00:00 - Biotech Daily Briefing

00:43 - RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
Rapport Therapeutics Reports Positive Phase 2 Results for RAP-219 in Bipolar Mania 2026-10-20:
https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htm
PolarityBio Phase 3 COVER DFUS II Meets Primary Endpoint in Diabetic Foot Ulcers 2026-10-20:
https://www.biospace.com/press-releases/polaritybio-highlights-highest-scoring-abstract-award-and-presentation-of-phase-3-cover-dfus-ii-trial-results-at-sawc-fall-2026

01:32 - RAP-219 Validates Selective Mechanism in Acute Mania

02:12 - Casdatifan Shows Efficacy in Renal Cell Carcinoma
Arcus Biosciences Presents ARC-20 Data for Casdatifan Across ccRCC Lines 2026-10-20:
https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm

03:02 - Casdatifan Delivers 35-Month Median Overall Survival

03:46 - Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
Teva and Sanofi Report 44-Week Phase 2b Data for Duvakitug in IBD 2026-10-20:
https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspx
Odyssey Therapeutics Reports Phase 2a OD-001 Data in Ulcerative Colitis 2026-10-20:
https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-ex99_1.htm

04:43 - FDA Approves Process 2.0 for Alvotech's SIMLANDI
Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process 2026-10-20:
https://www.biospace.com/press-releases/alvotech-receives-fda-approval-for-new-simlandi-manufacturing-process-that-more-than-doubles-output-per-batch

05:27 - Ambrose Acquires AM-Pharma for up to 161 Million Euros
Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million 2026-10-20:
https://www.biospace.com/press-releases/ambrose-healthcare-acquires-am-pharma-for-up-to-161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base

06:16 - Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
Nano24 Reports Positive Phase 2b Results for Inhaled EXO-CD24 in ARDS 2026-10-20:
https://www.businesswire.com/news/home/20261020667516/en/Nano24-Reports-Positive-Phase-2b-Results-for-Inhaled-EXO-CD24-in-Acute-Respiratory-Distress-Syndrome-ARDS-at-the-CHEST-Annual-Meeting-2026

07:06 - Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
Hengrui's Retlirafusp Alfa RELIGHT Phase 3 Results Published in JCO 2026-10-20:
https://www.hengrui.com/media/detail-1054.html

07:50 - Looking ahead
AstraZeneca and Oracle Launch Global AI Collaboration for Clinical Trial Optimisation 2026-10-20:
https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-oracle-launch-global-ai-collaboration-advance-clinical-trial-optimisation-support-better-patient-outcomes.html
Adocia Raises €7 Million and Extends Cash Runway to 2028 2026-10-20:
https://www.adocia.com/composants/uploads/2026/10/ADOCIA-PR-FINANCING-OPERATION-OCTOBER-2026.pdf

08:31 - SOZO Intuition

Daily - Oct 16, 2026 - Show Notes

Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com

CHAPTERS
00:00 Today's Biotech Brief Lead Stories
00:42 FDA Approves Roche's Enspryng for Thyroid Eye Disease
01:17 Enspryng Clinical Profile and SatraGO-2 Efficacy
02:03 Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
02:39 Revita Significantly Reduces Post-GLP-1 Weight Regain
03:26 Mankind Pharma Acquires Majority in Armed Cell
03:56 Armed Cell Platform and Strategic Leadership
04:39 Regulatory Moves: Zilbrysq Autoinjector and Talvey
05:49 Financings and M&A: City Therapeutics and Samsung
06:48 Looking ahead
07:36 SOZO Intuition Platform

SUMMARY

CHAPTERS AND SOURCES

00:00 - Today's Biotech Brief Lead Stories

00:42 - FDA Approves Roche's Enspryng for Thyroid Eye Disease
FDA approves Roche's Enspryng satralizumab, a first-in-class IL-6R inhibitor, as the first at-home subcutaneous treatment for thyroid eye disease 2026-10-16:
https://www.roche.com/media/releases/med-cor-2026-10-16

01:17 - Enspryng Clinical Profile and SatraGO-2 Efficacy

02:03 - Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
Fractyl Health reports that Revita met the six-month co-primary endpoint in the pivotal REMAIN-1 study, cutting weight regain after GLP-1 discontinuation…:
https://www.globenewswire.com/news-release/2026/10/16/3382499/0/en/fractyl-health-s-revita-meets-six-month-co-primary-endpoint-in-ongoing-remain-1-pivotal-study-with-highly-statistically-significant-reduction-in-weight-regain-after-glp-1-discontin.html
Opus Genetics presents positive clinical data from the OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 2026-10-16:
https://ir.opusgtx.com/press-releases/detail/545/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-

02:39 - Revita Significantly Reduces Post-GLP-1 Weight Regain

03:26 - Mankind Pharma Acquires Majority in Armed Cell
Mankind Pharma enters CAR-T with a EUR 48 million deal for a 70% stake in Belgium's Armed Cell Therapeutics 2026-10-16:
https://www.mankindpharma.com/media/press-release/mankind-pharma-to-acquire-majority-stake-in-armed-cell-therapeutics-marking-strategic-entry-into-next-generation-car-t-therapies/

03:56 - Armed Cell Platform and Strategic Leadership
Acepodia receives TFDA IND approval for ACE723, expanding clinical development to the United States, China and Taiwan 2026-10-16:
https://www.acepodia.com/newsroom-detail/ACE723_IND_TW/

04:39 - Regulatory Moves: Zilbrysq Autoinjector and Talvey
UCB receives U.S. FDA approval for ZILBRYSQ zilucoplan autoinjector self-administration in generalised myasthenia gravis 2026-10-16:
https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-for-zilbrysqr-zilucoplan-autoinjector-self-administration-for-adults-living-with-generalized-myasthenia-gravis
CHMP recommends approval of Johnson & Johnson's TALVEY talquetamab plus daratumumab in earlier-line relapsed or refractory multiple myeloma 2026-10-16:
https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma

05:49 - Financings and M&A: City Therapeutics and Samsung
Samsung Biologics publishes the definitive interim result of its tender offer for PolyPeptide with an 87.92% participation rate 2026-10-16:
https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-definitive-interim-result-for-polypeptide-tender-offer
City Therapeutics raises $200 million in an upsized initial public offering, the largest biotech IPO pricing of the week 2026-10-16:
https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html
Soufflé Therapeutics raises an oversubscribed $135 million Series B to advance its RNA delivery platform 2026-10-16:
https://www.citybiz.co/article/919851/souffle-therapeutics-raises-135m-to-advance-rna-delivery-platform/

06:48 - Looking ahead
Shareholders of Indivior and Supernus Pharmaceuticals approve their all-stock merger of equals 2026-10-16:
https://www.indivior.com/latest/category/company-statements/2026/indivior-shareholders-approve-proposed-merger-with-supernus
Edesa Biotech receives FDA IND clearance for a Phase 2 study of EB06 in vitiligo 2026-10-16:
https://www.biospace.com/press-releases/edesa-biotech-announces-fda-ind-clearance-for-phase-2-vitiligo-study
Eclipse Life Sciences reports positive Phase 2 BETTIS-1 topline results for EC-104 in diabetic macular edema 2026-10-16:
https://www.globenewswire.com/news-release/2026/10/15/3381495/0/en/eclipse-life-sciences-announces-positive-topline-results-from-phase-2-bettis-1-study-evaluating-ec-104-for-diabetic-macular-edema-dme.html
Additional references omitted to fit YouTube's 5,000-character limit.

This digest covers key developments from AstraZeneca, insitro, Takeda, Krystal Biotech, Labcorp Holdings and OMass Therapeutics, including a billion-dollar AI target-discovery collaboration, the first orexin agonist launch for narcolepsy type 1, positive early dermatology clinical data in Gorlin syndrome, a $722 million diagnostics asset acquisition, an FDA-accepted NDA resubmission and a $310 million Series C, alongside broader coverage across the sector. 

This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

This digest covers key developments from Zealand Pharma, Arrowhead Pharmaceuticals, Pharming, Galderma, and Alentis Therapeutics, including a billion-dollar AI-designed protein collaboration, first-in-human tau knockdown data, a positive Phase II immunology readout, and a $1.5 billion dermatology acquisition, alongside broader coverage across the sector. 

This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

This digest covers key developments from BioNTech, Samsung Biologics, Johnson & Johnson, and Formycon, including Phase III readouts, a cross-border tender offer, and regulatory acceptances, alongside broader coverage across the sector. 

This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

Featuring Bristol Myers Squibb, Roche, Viatris and Pacira Pharmaceuticals

Primary themes: Phase 3 clinical readouts, first-in-setting FDA approvals, and a non-opioid pain acquisition.

This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

Featuring Pfizer, Addex Therapeutics, Neurosterix and Microba Life Sciences

Primary themes: FDA regulatory approval, clinical product advancement, diagnostic product launch.

This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.